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Letters to the EditorDo fatigue and UDCA therapy truly have independent effects
on mortality in PBC?To the Editor:
We read with interest the paper by Jones et al. [1] regarding the
impact of fatigue and ursodeoxycholic acid (UDCA) treatment on
mortality in PBC. The authors are to be congratulated on their
accrual and close follow up of a well characterised group of
patients and their efforts have certainly expanded further our
understanding of the natural history and the effects of pharmaco-
logical interventions in PBC.
Nonetheless, caution must be exercised when evaluating their
dataset and conclusions, particularly in respect of the indepen-
dent effect of fatigue and UDCA usage on mortality for the follow-
ing reasons.
Firstly, whilst on univariate analysis both the presence of fati-
gue (which, importantly was identiﬁed here as a categorical var-
iable) and lack of use of UDCA were associated with increased
mortality, only 43 deaths were recorded. Consequently, the anal-
ysis of seven different variables in the Cox regression model is
possibly excessive and could lead to statistical errors in its output
as the ‘‘rule of thumb’’ of regression analysis has historically been
a minimum of 10 outcome events per variable. However, recent
reports suggesting the use of 5–9 outcomes per variable only
uncommonly lead to statistical error, though is slightly more
common with Cox models [2].
Secondly, fatigue, previously identiﬁed as categorical (present
or absent), is now interpreted as a linear score (based on the FIS)
as part of the Cox model. Therefore, although a 1 point increase in
the FIS is independently associated with an increased mortality
(risk ratio 1.008), how the presence (or otherwise) of fatigue
affects mortality in an independent model is not certain.
Thirdly, and perhaps most crucially, in this model, UDCA ther-
apy was not independently predictive of improved mortality at
all with a risk ratio of 0.728 (95% CI 0.370–1.432) p = 0.357. This
issue is of fundamental importance as it is at variance with the
very title of the manuscript.
On a ﬁnal note, the results in Table 1 suggests a possible typo-
graphical error in regard to the effect of age on mortality. The ini-Reply to: Do fatigue and UDCA t
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tigue and ursodeoxycholic acid (UDCA) treatment on mortal-
in PBC. Although they raise some interesting points, we
ve they may not fully understand the conclusions we made
ur paper. This is the largest series of patients with PBC fol-
d up for a considerable period of time, and this cohort has
Journal of Hepatologytial B value would suggest an increased risk for age and,
therefore, a risk ratio of >1, especially given the highly signiﬁcant
p value. However, the risk ratio of 0.728% and 95% CI of 0.37–
1.432 cannot provide such a highly signiﬁcant p value, given
the 95% CI clearly crosses 1.
In summary, whilst it remains possible that fatigue is indepen-
dently associated with increased mortality in PBC, the data pre-
sented by Jones et al. in its published format does not prove
that this is the case in respect of the presence or otherwise of fati-
gue. Furthermore, the use of UDCA therapy cannot be said to have
any independent effect on mortality, based on the published data.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
References
[1] Jones DE, Al-Rifai A, Frith J, Patanwala I, Newton JL. The independent effects of
fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of
a 9 year follow-up. J Hepatol 2010;53:911–917.
[2] Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in
logistic and cox regression. Am J Epidemiol 2007;165:710–718.
Fidan Yousuf
Andrew David Yeoman*
Prince Charles Hospital, Gastroenterology,
Gurnos, Merthyr Tydﬁl CF47 9DT,
United Kingdom
*Tel.: +44 7590489517
E-mail address: andrew.yeoman@wales.nhs.uk (A.D. Yeoman)herapy truly have independent
tality in PBC?
provided important insights into the true impact that fatigue
has on not only quality of life but also length of life.
Yousuf and Yeoman are correct, COX models can theoretically
be limited in their interpretation as the number of variables is
increased. If we had used this as our only analysis, we may have
agreed with them; however, combined with the Kaplan Meier
and Log Rank Test Analysis, which conﬁrm the relationship
between fatigue and mortality, we believe this enhances the
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